IDH1 and brain cancer: Meanwhile, the discovery of IDH1R132 has revolutionized neuropathological diagnostics [11], and the development of anti-IDH1 targeting strategies has matured into a new clinical strategy for long-term treatment success for some brain cancer patients [12], the knowledge of the biological roles of IDH1R132H, especially on possible tissue-dependent differences, is still incomplete.